Literature DB >> 27295374

The suitability of the Hospital Anxiety and Depression Scale, Distress Thermometer and other instruments to screen for psychiatric disorders in both lung cancer patients and their partners.

Melanie P J Schellekens1, Desiree G M van den Hurk2, Judith B Prins3, Johan Molema2, Miep A van der Drift2, Anne E M Speckens4.   

Abstract

BACKGROUND: Lung cancer patients and their partners report high rates of distress. Although distress is of importance, psychiatric disorders might be more important in terms of prognostic value and additional psychological treatment. This study examined the suitability of the Hospital Anxiety and Depression Scale (HADS), Distress Thermometer (DT), Beck Depression Inventory (BDI-II) and State subscale of State Trait Anxiety Inventory (STAI-S) to screen for psychiatric disorders in lung cancer patients and partners.
METHODS: A consecutive sample of lung cancer patients and partners completed the screening instruments. The Structured Clinical Interview DSM-IV (SCID-I) was used to diagnose psychiatric axis I disorders.
RESULTS: In 144 patients, overall ability of HADS total score (HADS-T) screening for patients with psychiatric disorders was good, whereas DT appeared less suitable. In 98 partners, the performance of HADS-T was good. Although no instrument was successful in identifying psychiatric disorders, HADS-T came closest with a fair performance in patients and partners. LIMITATIONS: Several patients and partners declined participation because they perceived participation as too distressing. As decliners possibly have the highest rates of disorders, our findings might underestimate the prevalence of psychiatric disorders. A low prevalence negatively affects the positive predictive value and complicates efficient screening for psychiatric disorders.
CONCLUSION: The HADS-T appears to be a suitable screening instrument for ruling out those lung cancer patients and partners without a psychiatric disorder. Regarding identifying those with a psychiatric disorder, HADS-T should be used to refer both patients and partners for further diagnostics and treatment to a psychiatrist/psychologist.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Distress Thermometer; Hospital Anxiety and Depression Scale; Lung cancer; Partners; Psychiatric disorder; Screening

Mesh:

Year:  2016        PMID: 27295374     DOI: 10.1016/j.jad.2016.05.044

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  19 in total

1.  Mental disorder screening on cancer patients before and after radiotherapy and at the 1-month follow-up.

Authors:  Juan Antonio Cruzado; Manuel Hernández-Blázquez
Journal:  Support Care Cancer       Date:  2017-09-23       Impact factor: 3.603

2.  The Sickness Behavior Inventory-Revised: Sickness behavior and its associations with depression and inflammation in patients with metastatic lung cancer.

Authors:  Daniel C McFarland; Leah E Walsh; Rebecca Saracino; Christian J Nelson; William Breitbart; Barry Rosenfeld
Journal:  Palliat Support Care       Date:  2021-06

3.  Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients.

Authors:  Daniel C McFarland; Devika R Jutagir; Barry Rosenfeld; William Pirl; Andrew H Miller; William Breitbart; Christian Nelson
Journal:  Psychooncology       Date:  2019-05-15       Impact factor: 3.894

4.  The use of the Distress Thermometer and the Hospital Anxiety and Depression Scale for screening of anxiety and depression in Italian women newly diagnosed with breast cancer.

Authors:  Cristina Civilotti; Daniela Acquadro Maran; Francesca Santagata; Antonella Varetto; Maria Rosa Stanizzo
Journal:  Support Care Cancer       Date:  2020-02-08       Impact factor: 3.603

5.  Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation.

Authors:  Daniel C McFarland; Devika R Jutagir; Andrew H Miller; William Breitbart; Christian Nelson; Barry Rosenfeld
Journal:  J Natl Compr Canc Netw       Date:  2020-04       Impact factor: 11.908

6.  C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.

Authors:  Daniel C McFarland; Kelly Shaffer; William Breitbart; Barry Rosenfeld; Andrew H Miller
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

7.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

8.  Physical problem list accompanying the distress thermometer: Its associations with psychological symptoms and survival in patients with metastatic lung cancer.

Authors:  Daniel C McFarland; Devika R Jutagir; Andrew Miller; Christian Nelson
Journal:  Psychooncology       Date:  2020-03-11       Impact factor: 3.894

9.  The patient acceptable symptom state in oral lichen planus: identification of cut-off threshold scores in measures of pain and quality of life.

Authors:  Paswach Wiriyakijja; Stephen Porter; Stefano Fedele; Tim Hodgson; Roddy McMillan; Martina Shephard; Richeal Ni Riordain
Journal:  Clin Oral Investig       Date:  2020-11-17       Impact factor: 3.573

10.  Prognostic Awareness in Caregivers of Patients with Incurable Cancer.

Authors:  Tamryn F Gray; Deborah Forst; Ryan D Nipp; Joseph A Greer; Jennifer S Temel; Areej El-Jawahri
Journal:  J Palliat Med       Date:  2020-09-30       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.